BD Announces First Fiscal Quarter Results; Raises Fiscal 2021 Guidance - First fiscal quarter revenues of $5.315 billion grew 25.8% on a reported basis. On a currency-neutral basis, revenues increased 24.3%. - BD's COVID-19 testing sales of $867 million contributed 20.5 percentage points to revenue growth on a reported basis. This includes BD Veritor™ Plus System revenues of $688 million. - First fiscal quarter GAAP diluted earnings per share (EPS) increased 285% year-over-year to $3.35. - Adjusted EPS increased 71.7% year-over-year to $4.55. - BD is updating its fiscal 2021 guidance, including raising its fiscal 2021 adjusted EPS guidance to $12.75-$12.85. News provided by Share this article Share this article FRANKLIN LAKES, N.J., Feb. 4, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $5.315 billion for the first fiscal quarter ended December 31, 2020. This represents an increase of 25.8% over the prior-year period on a reported basis and was primarily driven by the contribution of BD's COVID-19 diagnostic revenues, which totaled $867 million, contributing 20.5 percentage points to the company's total reported revenue growth in the quarter. On a currency-neutral basis, revenues increased 24.3%.